Egalet Licenses OXAYDO and Acquires SPRIX

Viatris Acquires Aculys Pharma to Secure CNS Assets and Japan/APAC Rights

October 15, 2025

Pharmaceuticals

Viatris Inc. has acquired clinical-stage Aculys Pharma, Inc., obtaining exclusive development and commercialization rights in Japan for pitolisant and rights in Japan and select Asia‑Pacific markets for Spydia (diazepam) nasal spray. The deal includes an upfront payment to Aculys shareholders with additional milestone and royalty payments, and is intended to strengthen Viatris' presence and CNS capabilities in Japan.

Nicox S.A. Acquires Aciex Therapeutics, Inc.

July 2, 2014

Pharmaceuticals

Nicox S.A. agreed to acquire Aciex Therapeutics, Inc., a U.S.-based ophthalmic development company, in a share-exchange deal that will transfer 100% of Aciex to Nicox. The transaction (approved by Nicox shareholders on October 22, 2014) issues 20,627,024 new Nicox shares for Aciex equity and includes contingent value rights giving up to $55 million in potential additional consideration tied to FDA approvals, and is intended to broaden Nicox's ophthalmic development pipeline.

HealthEdge Acquires Legacy-Xspire Holdings, LLC

December 18, 2019

Pharmaceuticals

HealthEdge Investment Partners, a Tampa-based healthcare-focused private equity firm, completed an acquisition of Legacy-Xspire Holdings, LLC, a Ridgeland, Mississippi-based branded and generic pharmaceutical marketing and distribution platform, on December 18, 2019. The deal adds a pharmaceutical marketing and distribution capability (combining WraSer Pharmaceuticals, Gentex Pharma, and Xpsire Pharma) to HealthEdge's portfolio to support organic growth and product acquisitions across the U.S.

Aeglea BioTherapeutics Acquires Spyre Therapeutics

June 22, 2023

Biotechnology

Aeglea BioTherapeutics completed a stock-for-stock acquisition of Spyre Therapeutics, a privately held biotechnology company advancing antibody therapeutics for inflammatory bowel disease (IBD). Concurrent with the acquisition Aeglea announced a $210 million PIPE led by Fairmount Funds to advance Spyre’s pipeline (lead programs SPY001 and SPY002) into clinical studies and fund operations into 2026.

Oragenics Acquires Odyssey Health Neurological Drug Assets

January 2, 2024

Pharmaceuticals

Oragenics, Inc. completed the acquisition of Odyssey Health, Inc.'s neurological drug therapy assets, including ONP-002, ONP-001 rights, a proprietary intranasal delivery device and related formulations. Odyssey retained its remaining assets and operations; Michael Redmond (former Odyssey CEO) was named President of Oragenics to oversee integration and advancement of the neurology pipeline as Oragenics prepares for Phase 2 studies of ONP-002.

Zevra Therapeutics Acquires Acer Therapeutics

November 20, 2023

Pharmaceuticals

Zevra Therapeutics completed the acquisition of Acer Therapeutics in a stock-and-contingent-value-rights transaction, bringing the FDA-approved product OLPRUVA and clinical-stage candidate EDSIVO into Zevra's portfolio and transitioning Zevra to a commercial-stage rare disease company. The deal included Zevra's purchase of Acer's senior secured debt and issuance of approximately 2.96 million shares plus CVRs (up to $76 million), and was followed by a registered direct offering to a healthcare-focused investment fund.